Setbone Medical
5 known investors
SetBone Medical is developing a new type of bone cement for treating vertebral compression fractures, which are primarily caused by osteoporosis. The product is aimed at physicians and intended to address limitations of existing bone cements.
Also known as SetBone · SetBone Medical Ltd · SetBone Medical Ltd.
Investors · 5
Also in the syndicate · 4
Company profile
researched Aug 2026SetBone Medical Ltd. is an Israeli company developing a new generation of acrylic bone cement for the treatment of Vertebral Compression Fractures (VCF), a vertebral collapse most commonly associated with osteoporosis that can cause severe pain and deformity. VCFs are treated with minimally invasive procedures such as vertebroplasty and kyphoplasty, in which bone cement is injected through a hollow needle into the fractured vertebra to stabilize and strengthen it. The company positions its cement, referred to as ReadySet, for use across a wider range of orthopedic and spine procedures, with VCF as the first product indication.
Conventional acrylic bone cements consist of a liquid monomer and a copolymer powder that must be mixed in the operating room. According to the company, this process releases toxic monomers, produces inconsistent viscosity, leaves surgeons only a few minutes of working time, and generates heat during curing that can damage surrounding tissue. SetBone's proprietary formulation contains no free toxic monomers, arrives in a ready-to-use prefilled cartridge requiring no on-site preparation, uses a dual-paste mix-on-injection design for extended working time, and has a low exothermic reaction. It is intended to be used with the same surgical approach and tools as existing cements.
The company is a portfolio company of The Trendlines Group and was founded by Nimrod Kaufmann (CEO) and Royi Kaufmann, PhD (CTO). Its bone cement is described as patent-pending, and proceeds from its January 2022 financing were designated to advance development and initiate a First in Human pilot study, with FDA clearance cited as a development goal.
Founding story
SetBone Medical was founded by Nimrod Kaufmann and Royi Kaufmann, PhD. Nimrod Kaufmann serves as CEO and is described as a founder and previous CEO of Inspiro Medical Ltd.; Royi Kaufmann is CTO and holds a PhD in physical chemistry with experience in polymers development.
Traction
As of the January 2022 financing, the company had a patent-pending bone cement in development and planned to initiate a First in Human pilot study; no commercial availability or regulatory clearance is reported.
Latest developments
In January 2022, SetBone announced the close of an oversubscribed $1.6 million investment round with participation from The Trendlines Group, Agriline, Chicago ArchAngels and other private investors, to fund the next development stage and initiation of a First in Human pilot study.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
The company targets the bone cement market, which its financing announcement cited as projected to reach $1.4 billion by 2028 and described as a $1 billion+ market. It positions its product against existing liquid/powder acrylic cements on the basis of monomer toxicity, preparation requirements, viscosity consistency, working time and curing temperature. Vertebral compression fractures are cited at approximately 1.4 million per year globally, of which more than 750,000 occur in the United States.
Absence of free toxic monomers, a ready-to-use prefilled cartridge requiring no on-site preparation, dual-paste mix-on-injection delivery with extended working time and consistent viscosity, and a low exothermic curing reaction, while retaining the same surgical procedure and instruments used with current cements.
Technology
SetBone's technology is a proprietary acrylic bone cement that contains no free toxic monomers, in contrast to conventional liquid-monomer/copolymer-powder systems mixed in the operating room. It is supplied in a prefilled, ready-to-use cartridge and uses a dual-paste formulation that mixes on injection, providing extended working time and consistent viscosity. Its low exothermic reaction is intended to keep curing temperature low and avoid thermal damage to surrounding tissue. The cement is patent-pending and is designed for use with existing surgical approaches and tools.
Go-to-market
Physicians performing minimally invasive spine and orthopedic procedures such as vertebroplasty and kyphoplasty, and the patients they treat for osteoporotic vertebral compression fractures.
Geography
Headquartered in Israel, at Ness-Ziona Business Park, 7 Pinhas Sapir St., with the company's financing announcement datelined Tel Aviv. The first target indication references the United States market for vertebral compression fractures.
History
The company was established in 2017 in Israel as a portfolio company of The Trendlines Group. In January 2022 it announced the close of an oversubscribed $1.6 million investment round, intended to fund the next stage of development and the initiation of a First in Human pilot study toward FDA clearance.
Risks & controversies
The product is pre-commercial and has not received FDA clearance; the company stated in January 2022 that it was still working toward a First in Human pilot study and regulatory clearance.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsSetBone Medical announced the close of an oversubscribed $1.6 million investment round with investors including The Trendlines Group, Agriline (a trust of which Vincent Tchenguiz is a discretionary beneficiary), Chicago ArchAngels and other private investors. Proceeds were designated for the next stage of development and initiation of a First in Human pilot study.
$1.6M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Setbone Medicalsetbone.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Setbone Medical do?
- Israeli medical device company developing a ready-to-use acrylic bone cement for vertebral compression fractures.
- Who are Setbone Medical's investors?
- Setbone Medical's investors include Trendlines Group.